Kalohexis Strengthens Leadership with Appointment of Dr. Jeffrey Sherman to Board

Kalohexis Appoints Dr. Jeffrey Sherman, MD to Board of Directors

Kalohexis, Inc., a clinical-stage biotechnology firm, has announced the strategic appointment of Dr. Jeffrey Sherman to its Board of Directors. This decision marks a significant step for Kalohexis as it strives to revolutionize the treatment landscape for metabolic disorders, starting with conditions such as obesity and cancer cachexia.

In a statement, Russell Potterfield, CEO of Kalohexis, expressed his excitement about Dr. Sherman joining the board. He highlighted Sherman’s extensive background and expertise gained over 35 years in research and development, particularly in regulatory strategy and rare disease therapeutic development. Potterfield stated, "Jeff is a distinguished industry leader who brings valuable experience to Kalohexis' Board of Directors. We are thrilled to welcome Jeff and look forward to leveraging his deep expertise as we advance our pipeline of therapeutic peptide candidates."

Dr. Sherman’s impressive career includes high-profile roles such as Executive Vice President and Chief Medical Officer at Horizon Therapeutics, which he led until its acquisition by Amgen. His previous experience also encompasses leadership roles at IDM Pharma and Takeda Global Research, among others. In addition to his corporate roles, he has been actively involved in major regulatory discussions, serving in key organizations like the Drug Information Association (DIA) and the FDA-sponsored Clinical Trial Transformation Initiative (CTTI).

Reflecting on his new role, Dr. Sherman expressed his optimism about Kalohexis’ innovative approach to metabolic disorders via the melanocortin system, stating, "Kalohexis' proprietary know-how for safely and effectively targeting the melanocortin system… could offer new hope to millions of people with metabolic disorders." His commitment to working closely with the Kalohexis leadership signifies a dynamic path forward for the company’s initiatives in addressing metabolic health challenges.

Currently, Dr. Sherman also holds positions on the boards of several biotech firms, including Sorriso Pharmaceuticals and Larimar Therapeutics. His academic credentials include a medical degree from Chicago Medical School and extensive training in internal medicine and infectious diseases at Northwestern University and UCSF.

Kalohexis, which spun out of Endevica Bio in March 2026, is particularly focused on advancing treatment for obesity, which affects a large segment of the population, and cachexia in cancer patients. Their lead projects include 710GO, an oral dual agonist aimed at promoting substantial weight loss in obesity, and mifomelatide, a dual antagonist targeting cachexia in advanced cancer cases. These advancements are poised to leverage the melanocortin pathways in the body, signaling a new frontier in metabolic medicine.

For more insights on Kalohexis and its promising pipeline of therapeutics, you can visit their official website or follow their updates on social media platforms.

This strategic move to incorporate leading industry professionals into Kalohexis’ board underscores the company's commitment to fostering innovation and improving health outcomes for individuals suffering from metabolic disorders. The leadership change symbolizes a proactive approach to ensuring that the organization remains at the forefront of biotechnology advancements and therapeutic developments, ultimately benefiting patients who are in dire need of effective metabolic disease solutions.